Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 9Skin Neoplasms 2Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Skin Neoplasms × Vinblastine × Dermatologic × Clear all
NCT00885534 2015-05-06

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
7 enrolled 6 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT00002882 2011-12-13

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

M.D. Anderson Cancer Center

Phase 3 Completed
140 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡